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BACKGROUND: Activins and inhibins belong to the TGFb-superfamily, which controls cell proliferation and differentiation in
many organs. Activin A, the dimer of inhibin bA subunit, acts strongly anti-proliferative in hepatocytes. Little is known on the other
activin/inhibin subunits in human liver and hepatocellular carcinoma (HCC).
METHODS: We studied the expression of the complete inhibin family a, bA, bB, bC, bE in normal liver, tumour-adjacent and
HCC tissue, 12 additional organs and rodent liver. A total of 16 HCC and 10 disease-free livers were analysed. Expression of
inhibin subunits was determined by qRT–PCR, normalised to RNA input and by geNorm algorithm, and confirmed by
immunohistochemistry.
RESULTS: Remarkably, bA expression was not decreased in HCC. Similarly, bC and bE exhibited no major changes. In contrast, inhibin a,
barely detectable in normal liver, was strongly increased in tumour-adjacent liver and dramatically enhanced in HCC. bB was strongly
enhanced in some HCC. At variance with human liver, rodent liver showed higher inhibin a and bC expression, but bA was
somewhat, and bB dramatically lower.
CONCLUSIONS: Upregulation of inhibin a – and possibly of bB – may shield HCC cells from anti-proliferative effects of activin A.
Dramatic variations between humans and rodents may reflect different functions of some inhibins/activins.
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Liver cancer is among the leading causes of cancer deaths world-
wide. It is characterised by deregulation of proliferation and
apoptosis of hepatocytes and usually develops on the basis
of chronic tissue inflammation leading to fibrosis and cirrhosis
(Grasl-Kraupp et al, 2000; Drucker et al, 2006; Seitz and Stickel,
2006; Herzer et al, 2007). The underlying molecular mechanisms
are barely understood (Strand et al, 1996; Laurent-Puig and
Zucman-Rossi, 2006; Macheiner et al, 2006). Their elucidation is
critical for the development of improved therapies for liver cancer
(Schulte-Hermann et al, 1997; Llovet et al, 2003; El-Serag and
Rudolph, 2007).
Activin and inhibin proteins are members of the TGFb
superfamily, which controls cell proliferation, apoptosis, inflam-
mation and differentiation in many cell types and organs including
the liver (De Bleser et al, 1997; Schulte-Hermann et al, 1997;
Rodgarkia-Dara et al, 2006; Deli et al, 2008). The mammalian
inhibin family includes one a- (INHA) and four b-genes (INHBA,
INHBB, INHBC and INHBE). Gene products dimerise to form
inhibin and activin proteins. Inhibins are heterodimers consisting
of the a-subunit and one b-subunit, forming inhibin A (a-bA) and
inhibin B (a-bB). Activins are homodimers (activin A¼bA–bA,
activin B, C and E) or heterodimers (e.g., activin AB¼bA–bB) of
two b-subunits (Grusch et al, 2007). At the mRNA level, INHA is
most prominently expressed in ovary, testis, adrenal and pituitary
gland but reportedly not detectable in human and rodent liver
(Meunier et al, 1988; Tuuri et al, 1994). Expression of INHBA
mRNA is usually high and found in many organs including the
liver. Similarly, INHBB mRNA has been detected in many organs
but in rodent liver low or undetectable levels or only transient
appearance on diverse treatments were reported (De Bleser et al,
1997; Kobayashi et al, 2000, 2002; Vejda et al, 2002; Jones et al,
2007). In contrast, INHBC and INHBE expression levels are highest
in the liver, much lower in testis, adrenal and pituitary gland and
almost undetectable in other organs of rodents (Fang et al, 1997;
Vejda et al, 2002; Gold et al, 2004). In human tissues, comparisons
of INHBB, INHBC and INHBE expression apparently have not been
reported.
The resulting activin proteins may have important functions in
the human liver, which are, however, still unknown except for
activin A. Activin A is considered a key inhibitor of liver growth
(Yasuda et al, 1993; Xu et al, 1995; Zauberman et al, 1997), whereas
the so-called liver-specific activin C and activin E were reported
to either promote (Wada et al, 2004, 2005) or inhibit hepato-
cyte proliferation (Chabicovsky et al, 2003; Vejda et al, 2003).
After partial hepatectomy in mice nulled for INHBC,o rINHBE
and or for both no alterations in liver regeneration was observed
(Lau et al, 2000). Studies on expression of INHBC and INHBE
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smRNA during liver regeneration after partial hepatectomy
(Esquela et al, 1997; Zhang et al, 1997; Kogure et al, 1998; Lau
et al, 2000; Gold et al, 2005; Takamura et al, 2005; Wada et al,
2005), or chemical injury (Kobayashi et al, 2002; Gold et al, 2003;
Grusch et al, 2006) in rodents produced conflicting data on
possible biological functions as reviewed recently (Grusch et al,
2007). Most of the information available were gathered in rodent
liver and rarely confirmed in humans (Tuuri et al, 1994).
Recently, we reported that INHBA and INHBE were down-
regulated in chemically induced hepatocarcinogenesis in rats
(Grusch et al, 2006). However, in patients with cirrhosis and
hepatocellular carcinoma (HCC) elevated levels of serum activin A
were observed and were suggested as biomarkers of liver disease
(Pirisi et al, 2000; Yuen et al, 2002). Similarly, in several other
malignancies deregulation of inhibin and activin at the mRNA and
protein level is a common event, including tumours of endometrial
(Worbs et al, 2007), adrenocortical (Salmenkivi et al, 2001;
Hofland et al, 2006, 2007) and gonadal stromal origin (Fuller
et al, 1999; Fine and Li, 2003; Ciris et al, 2004).
Consequently, in this study we analysed by qRT–PCR
mRNA expression patterns of the inhibin family in human liver,
HCC-adjacent fibrotic/cirrhotic tissue, and HCC. For comparison,
inhibin expression patterns were also analysed in additional
human tissues and in mouse and rat liver. To our knowledge, this
is the first analysis of the entire inhibin family in human liver and
HCC. To overcome problems resulting from uneven expression of
reference genes in normal, tumour-adjacent and malignant tissue,
we standardised gene expression by referring to total RNA input
and by normalisation with the geNorm protocol. The results
provide a distinct molecular expression portrait of the inhibin gene
family in disease-free liver, HCC, other organs and rodent liver.
Unexpectedly, INHA, barely detectable in disease-free liver, was
strongly elevated in most HCC samples. INHBB, extremely low in
rat liver, was highly expressed in human liver and further upregu-
lated in most HCC. These results provide important new clues to
functions of the inhibin/activin family in liver and HCC.
MATERIALS AND METHODS
Tissue samples
A total of 16 HCC (tumour, T) and tumour-adjacent (non-tumour,
NT) liver samples, plus 5 normal (N) liver specimens were obtained
from patients of the General Hospital, Vienna, in the Austrian ‘Gen-
Au Programme’ (Macheiner et al, 2006; Sagmeister et al, 2008).
Patient information’s are listed in Table 1. Written informed consent
was obtained from each patient. Additionally, 5 RNA samples were
purchased, providing overall 10 normal liver specimens.
All cancer samples contained at least 80% tumour cells as shown
by histology. In all, 6 tumours were classified as stage I, 7 as stage
II, 1 as stage III and 2 as stage IV, and histological grading was
2 HCC-1, 13 HCC-2 and 1 HCC-3, according to AJCC/UICC
standards and (Edmondson and Steiner, 1954). Hepatocellular
carcinoma-adjacent tissue was cirrhotic in seven cases and fibrotic
in nine cases. Human RNA from normal liver and 12 additional
organs was from BioCat (Heidelberg, Germany), Clontech
(Mountain View, CA, USA) and Stratagene/Agilent Genomics
(Santa Clara, CA, USA). Liver samples from C57BL/6 mice and
Wistar rats were obtained as described (Grusch et al, 2006).
In total, 5 out of 16 samples described above were available for
immunhistochemical analyses. In addition, a commercially available
HCC tissue array (Biochain, Hayward, CA, USA) was used. This array
contains 16 pairs of tumour and adjacent tissue sections (1 stage I and
15 stage II tumours). A human ovarian granulosa cell tumour
(Biogenex , Fremont, CA, USA) served as positive control for inhibin a.
RNA isolation
Total RNA was isolated using TRIzol reagent (Invitrogen/Life
Technologies, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Tissue samples were prepared using a homogeniser
(Bertin Technologies, Montigny-le-Bretonneux, France). High
quality of RNA samples were carefully controlled on GenQuant
(Pharmacia/GE Healthcare Life Science, Stockholm, Sweden). All
samples of RNA were protein free as indicated by absorbance ratio
260/280nm of 1.8–2.1. The mean error of triplicate measurements
of RNA concentration of all samples (n¼42) was 8.0%. The
integrity of all RNA samples was confirmed electrophoretically on
1.5% agarose gel (data not shown).
Reverse transcription and quantitative real-time PCR
Two micrograms of total RNA was reverse transcribed with MMLV
RevertAid (Fermentas/Thermo Scientific, St Leon-Roth, Germany)
resulting in 100ml cDNA solution. In all, 2ml cDNA solution was
used as template for each PCR. Real-time analysis was performed
with TaqMan Universal PCR Master Mix (Applied Biosystems/Life
Technologies, Carlsbad, CA, USA) on an ABI Prism 7000 Sequence
Detection System (Applied Biosystems/Life Technologies) running
the following protocol: initial 501C for 2min and 951C for 10min,
and 40 repeats of 951C for 15s, 601C for 1min. Taqman assays
used in this study are listed in Supplementary Table 1. All samples
were analysed in duplicate and in at least two independent real-
time PCR runs. The intra-assay mean error was 0.16% and the
inter-assay mean error 1.24%.
Calculation of expression data
Original (raw) cycle threshold values Ct refer to 100ng of total high
quality RNA input (designated ‘normalised to RNA input’). They
were transformed by the following procedures. For each gene, the
median Ct value of data from normal liver samples (n¼10) was
used as calibrator. Each single sample Ct value was logarithmically
transformed, calculated by the formula 2
 (calibrator–sample), and
expressed as fold change vs the median of disease-free liver Ct. For
normalisation with reference genes, samples were transformed as
described (Vandesompele et al, 2002). As expression of standard
reference genes in normal and malignant liver showed large
variations, we determined the most stable one using geNorm
applet. For normalisation, the transformed data of inhibin genes
were divided by the respective normalisation factors (NFs). The
following genes were used for normalisation: for N samples B2M,
ACTB and HPRT, for NT and T samples GAPDH, HPRT and TBP
(additional information in Supplementary Figure 1). Subsequently,
data from NT and T samples were normalised by using NF. The
median of normalised data from disease-free liver samples was
used as calibrator and set 1. Two different sets of NF were obtained
by either assuming NT and T samples as one group, referred to as
‘NF jointly’, or as separate subgroups NT and T, referred to as ‘NF
Table 1 Characteristics of controls and HCC patients
Controls (normal liver) HCC patients
Number 10 16
Sex
Female 4 6
Male 6 10
Age at operation
Mean±s.d. 50.5±6.6 63.4±12.4
Range 45–64 43-78
HBV infected 0/10 0/16 (0%)
HCV infected 0/10 5/16 (31%)
Abbreviations: HBV¼Hepatitis B virus; HCC¼hepatocellular carcinoma;
HCV¼Hepatitis C virus.
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sseparately’. Changes in expression levels in NT and T from HCC
patient’s normalised by geNorm or to RNA input are compared
in Table 2.
For species and tissue comparisons, Ct values normalised to
RNA input were used. The results from the lowest expressing
tissues were set 1 after logarithmical transformation. Results from
all other samples were expressed as fold change.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 4.0
for Windows (http://www.graphpad.com). Data of all three groups
(N, NT and T) were analysed by Kruskal–Wallis test. Significance
of differences between medians of non-paired groups (N and NT,
N and T) was checked using the non-parametric Mann–Whitney
U-tests. Results from paired NT and T samples were analysed by
the non-parametric Wilcoxon matched pair test. Correlation
between gene expression levels and ratios was checked by the
Spearman ranked test. All tests were performed as two-tailed and
statistical significance was assumed at Po0.05.
Immunohistochemistry
Histological staining was performed as previously described
(Grusch et al, 2006). In brief, tissue samples were fixed in 4%
buffered formalin, embedded in paraffin, 2mm sections were
deparaffinised and antigen-retrieval was done by heating in 0.01 M
citrate buffer, pH 6.0. Sections were incubated overnight at 41Ci n
0.1% BSA/PBS with primary antibodies against inhibin a-subunit
(clone R1, LabVision/Neomarkers/Thermo Scientific, Fremont,
CA, USA) diluted 1:20 and activin/inhibin bB subunit (R&D
Systems, Minneapolis, MN, USA) diluted 1:100. Then, sections
were washed in PBS with 0.5% Tween 20 and incubated with
HRP-coupled secondary anti-mouse antibody (Dako, Glostrup,
Denmark) diluted 1:200. DAB was used as chromogen to detect
peroxidase activity. Sections were counterstained with haematoxylin
and mounted in Dako mounting medium (Merck, Darmstadt,
Germany).
Rabbit polyclonal activin/inhibin bE subunit antibody was kindly
provided by W Schneider (Grusch et al, 2006). Staining for activin/
inhibin bE (primary antibody, dilution 1:500) and activin/inhibin
bA (Serotec, Duesseldorf, Sweden, mouse monoclonal, dilution
1:50) was performed as described above except that biotinylated
instead
of HRP-coupled secondary antibodies were used and sections
subsequently incubated with streptavidin–HRP conjugates.
For staining of the tissue arrays, fixed in 10% formalin, the
more sensitive Ultravision Detection System (LabVision/Thermo
Scientific) was used. Antigen retrieval and the concentration of the
primary antibodies were the same as described above. Activin/
inhibin bC immunocytochemistry was not studied because of the
lack of reliable antibodies. All available antibodies gave a positive
response in INHBC knockout mice suggesting cross reactivity with
other protein(s) (unpublished).
RESULTS
Expression of the inhibin family in normal and
tumour-adjacent liver and in HCC
We have previously studied INHBA and INHBE expression in
11 samples of human HCC and two disease-free livers (Grusch
et al, 2006). We now extended our analysis to all inhibin family
members and to tumour-adjacent (fibrotic or cirrhotic) tissue, and
increased sample numbers (16 HCC, 10 normal liver specimens).
PCR results are displayed in Figure 1. B2M is included here, as it
was used as reference gene in the previous study.
INHA (inhibin a) mRNA, reportedly undetectable in rat liver
(De Bleser et al, 1997), was found in 7 out of 10 normal (N) liver
samples, range of Ct values 33.5–36.5, in 15 out of 16 adjacent tissues
(NT), Ct 30.5–39.5, and in all HCC (T), Ct 24.5–36 (Figure 1A).
Thus, INHA expression was strongly upregulated in NT and even
more in T (significant for N–NT and N–T). Expression of the four
b subunits was detected in all samples, Ct 20.5–35.5. No significant
changes vs N were seen in NT or T. However, T vs NT in paired
samples showed significant upregulation of INHBA, INHBB and
INHBE, whereas INHBC expression remained unaltered.
Expression changes in individual NT and T samples vs the
median of normal liver are shown in Figures 1B and C, respec-
tively. INHA expression varied considerably, particularly in HCC.
Overall, it was increased in all but three NT samples, and in all but
two T samples, resulting in mean 9- and 225-fold increases in NT
and T, respectively (Table 2, left columns). Similarly, INHBB was
Table 2 Changes in expression of inhibin genes in tumour-adjacent and HCC samples calculated with different normalisation methods
Normalised to RNA input NF separately NF jointly
NT T NT T NT T
INHA 9.0±2.9 225±148 6.2±3.3 140±83 5.1±2.1 357±291
3.7 10.9 2.3 8.6 2.3 8.9
Wmp*, MW–NT*, MW–T** Wmp**, MW–T* Wmp**, MW–T*
INHBA 0.61±0.14 1.9±0.46 0.68±0.17 6.3±3.7 0.77±0.20 3.9±1.4
0.56 0.97 0.55 2.3 0.63 1.8
Wmp* Wmp** Wmp**
INHBB 4.0±1.7 12±4.0 2.5±1.0 30±19 2.8±1.2 16±7.6
1.23 4.3 0.64 3.5 0.72 4.3
Wmp* Wmp** Wmp**
INHBC 1.3±0.51 1.7±0.52 1.1±0.38 3.4±1.5 1.3±0.43 2.2±0.64
0.73 0.98 0.71 1.3 0.81 1.4
—— —
INHBE 1.2±0.33 3.1±1.6 0.80±0.33 3.1±1.1 0.90±0.37 2.0±0.72
0.94 1.7 0.40 0.76 0.46 0.65
Wmp* Wmp** —
Abbreviations: HCC¼hepatocellular carcinoma; MW–NT¼Mann–Whitney U-test comparing N and NT samples; MW–T¼Mann–Whitney U test comparing N and T
samples; N¼normal; NF¼normalisation factor; NT¼non-tumour; T¼tumour; Wmp, Wilcoxon matched pair test comparing NT and T samples. *P-value o0.05; **P-value
o0.01. Values are given relative to the median mRNA expression value in normal liver tissue as means±s.e.m. (first row) and medians (second row).
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supregulated in a fraction of the HCC, resulting in an overall mean
12-fold increase, while other HCC exhibited no change or even
decreases. Expression of INHBA, INHBC and INHBE was increased
in some and decreased in other HCC, overall no significant
changes were noted. Expressions in paired NT and T samples from
individual patients are displayed in Supplementary Figure 2. The
strong upregulation in HCC of INHA and the weaker increases of
INHB genes except INHBC are clearly seen (compare Figure 1A).
The increase in INHBE was significant with only two normalisation
methods, see below (Table 2).
Expression of INHBB and INHBC was correlated in NT
(r¼0.897, P¼3 10
 6) and in T (r¼0.924, P¼6 10
 7). INHA
and INHBA expression was correlated in NT samples (r¼0.782,
P¼0.0006), but not in T. Overall, obvious correlations between
expression levels of the genes studied clinical parameters such as
gender, age, tumour staging, tumour grading, viral and fibrotic/
cirrhotic status were not detected.
The present data showing no significant change in expression
of INHBA and INHBE in HCC seem to vary with our previous
study in which decreases for these two genes were reported
(Grusch et al, 2006). These variations are most likely due to a
difference in normalisation which was performed here to RNA
input, but previously to B2M. When normalising the present
results with B2M, downregulation from N to T appeared again,
obviously a consequence of the pronounced increase in B2M
expression in HCC. We conclude that a single reference gene
may be unsuitable for normalisation of RNA expression data in
human HCC.
Normalisation by geNorm
In Figure 1, we display RNA data normalised to RNA input or data
derived therefrom by logarithmical transformation according to
(Tricarico et al, 2002). In addition, we applied a normalisation
protocol based on combinations of reference genes determined
by geNorm (Vandesompele et al, 2002), as developed for HCC
(Supplementary Figure 1).
As five of the six chosen reference genes are significantly
upregulated even in non-tumourous tissue from HCC patients
(data not shown), the use of one combination of reference genes
for N, NT and T samples together would lead to an general over-
estimation of gene expression level in the disease-free liver
samples. Normalisation within a subgroup, like N, with an opti-
mised reference gene combination (Supplementary Figures 1A
and B for NT samples) results in reduced statistical spread
of expression of inhibin genes, rather than in shift of the median
expression, which varied between 0.86 and 1.22 only after
normalisation for N samples (Supplementary Figure 1C). For NT
and T samples, the same three reference genes were found as the
most stable ones (data not shown). The stability values S calculated
for NT samples alone was far below the recommended threshold
of 1 (Hellemans et al, 2007). However, when T samples were
included into the calculation S-value increase dramatically,
reflecting deregulation of reference gene expression (data not
shown). Consequently, we used two different sets of normalisation
factors, ‘NF jointly’ and ‘NF separately’, compared the results with
those obtained by normalisation to RNA input. Overall, results
varied in a reasonable range, indicating the reliability of the three
normalisation methods used. Specifically, the strongest increase
in median expression was consistently found in tumour samples
for INHA ranging from 8.6- to 10.9-fold. Significant expression
changes between NT and T were observed with INHBA and INHBB,
and in part for INHBE (Table 2).
Inhibin protein expression in HCC
To confirm expression of inhibin genes at the protein level, we
performed immunohistochemistry on a subset of the NT and
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Figure 1 mRNA expression of inhibin genes in disease-free (N), and
tumour-adjacent (NT) liver and in HCC (T). (A) Real-time PCR cycle
threshold (Ct) values normalised to RNA input are given. Ct values for B2M
are shown for comparison. Boxes (blank, N; dotted, NT; grey; T) represent
the lower and upper quartiles with medians; whiskers illustrate the 10–90
percentiles of the samples. Significant changes (Po0.05) are marked with
brackets and asterisk. (B and C) Expression changes of individual NT or T
samples related to the median of normal liver (N). Log transformed Ct
values were used. Dotted lines indicate expression changes to 42-fold or
o0.5-fold, considered as thresholds of biological relevance. INHA levels in
three N and one NT samples were undetectable and for calculations were
set at the detection limit (Ct 40).
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sT samples used for mRNA expression analysis (indicated in
Supplementary Figure 2) and on a HCC tissue array from an
independent patient collective. For inhibin a, we choose one HCC
with the highest mRNA level and one moderately expressing one,
as we expected to work at the detection limit. Moderate staining in
almost all carcinoma cells was detected in the highly expressing
HCC (Figure 2A (i)), whereas the moderately expressing tumour
exhibited very intense staining in a restricted number of
carcinoma cells (Figure 2A (iii)). Also in 2 of 16 samples from
the tissue array, strong staining in restricted areas was detected
(Supplementary Figure 3B). The adjacent tissue samples were
either negative for inhibin a or showed a very faint parenchymal
staining (Figure 2A, Supplementary Figure 3A, Supplementary
Table 2).
For activin/inhibin bB, three representative NT samples
expressing high, moderate and low mRNA were stained and the
intensity of the staining correlated well with INHBB mRNA levels
(Supplementary Figure 3B). In general, activin/inhibin bB staining
was intense in cells from parenchymal origin in both, tumour and
adjacent tissue. A semi-quantitative analysis of the tissue array
data demonstrated upregulation in 7, downregulation in 4 and an
unaltered expression in 5 of 16 tumour array samples (Supple-
mentary Table 2), a similar distribution as found for mRNA
expression in the independent HCC collective used for RNA
analysis (Figure 1C).
Expression of activin/inhibin bA and bE protein subunits was
studied in five pairs of T and NT samples. In all specimens,
carcinoma cells and the parenchymal cells of the adjacent tissues
were clearly positive for both proteins (Figure 2B). For both
protein subunits, the staining intensities in the tissue array ranged
from negative to very strong staining in tumour as well as adjacent
tissues (Supplementary Table 2). With all activin/inhibin subunits,
staining was restricted to carcinoma cells, hepatocytes and bile
ductular cells; whereas mesenchymal cells were consistently
negative. As the antibodies detect inhibin subunits, the composi-
tion of the dimeric proteins cannot be deduced.
Inhibin gene family expression in various human tissues
Expression of inhibin family members was analysed in 12
additional human organs and normalised to RNA input. Results
including levels in normal liver and HCC are shown in Figure 3.
INHA expression was highest in testis, as reported previously
(Meunier et al, 1988; Tuuri et al, 1994), exceeding levels in HCC
about 250-fold and in normal liver about 2500-fold; lowest levels
were measured in colon. All four b subunits were highly expressed
in the liver. INHBA and INHBB were detected in almost every
tissue sample with a remarkably similar overall pattern. INHBC
and INHBE expression were at least 100-fold higher in liver than in
any other organ investigated, but nevertheless detected in 11 out of
13 and 9 out of 13 tissues, respectively. Thus, INHBC and INHBE
are predominantly, but not specifically expressed in the liver as
assumed previously.
Inhibin family gene expression differs in human and
rodent liver
For comparison, expression of the inhibin family was analysed in
mouse and rat liver. To test for species differences in qRT-PCR-
based Ct values, distinct plasmid dilution series were performed
and revealed detectability at similar Ct levels (data not shown). As
displayed in Figure 4, INHA expression, overall at a low level, was
about 10-fold higher in rodent than in human liver. INHBC and
INHBE were highly expressed in all three species, with INHBC
levels being about 10-fold higher in rodent than in human liver. In
contrast, INHBA and INHBB expression was more pronounced
in human than in rodent liver, levels being 10- and 100-fold lower
in mice. In rats, INHBA levels were only slightly lower than in
humans while INHBB expression was extremely low, detectable
only at Ct 37.5. Taken together, there are profound interspecies
differences in basal hepatic expression of inhibin genes.
DISCUSSION
The involvement of members of the TGFb superfamily in
hepatocellular carcinogenesis is well established (Teicher, 2001;
Rodgarkia-Dara et al, 2006), but the individual players and their
functions and mechanisms of action are still largely unknown.
Here, we analysed the expression of the complete inhibin family in
human liver and HCC, other human organs and rodent liver.
Care was taken to assure the validity of comparisons between
liver and HCC as well as between different tissues or species. As
also reported by several groups the usual reference genes are not
stably expressed during stages of cancer development (Blanquicett
et al, 2002; Ohl et al, 2005; Waxman and Wurmbach, 2007). The
use of a single reference gene for normalisation of RNA data may
lead to unreliable or even wrong conclusions. We suggest an
adapted normalisation approach especially for comparison of
disease-free liver with fibrothic/cirrhotic liver and HCC. Here, we
show that these normalisation procedures yield similar results as
normalisation to RNA input of carefully controlled quality. This
similarity confirms the overall validity of the results. In agreement
with other authors (Tricarico et al, 2002; Caradec et al, 2010), we
conclude that normalisation to RNA input provides reliable
results. However, when studying new systems validity may be
rechecked with normalisation protocols such as geNorm.
We also confirmed the validity of interspecies comparison of
inhibin expression in the liver (see Results), which is supported by
earlier studies reporting weak or undetectable expression of INHA
and INHBB in rat liver by northern or RNA protection assays
(De Bleser et al, 1997; Kobayashi et al, 2000; Vejda et al, 2002).
Overall, our study revealed remarkable interspecies differences in
expression levels of some inhibins, in particular INHA, INHBA and
INHBB. As these differences may reflect variant roles in human
and rodent liver care should be taken when extrapolating results
from rodents to humans. This conclusion is supported by recent
work (Utoh et al, 2010). In a mouse xenotransplant model, human
hepatocytes replaced dying mouse cells excessively resulting in
liver growth to three times the normal size, while rat hepatocytes
terminated growth at normal liver size. This was explained by
failure of human, but not rat hepatocytes to upregulate TGFb and
activin A type II receptors.
Inhibin and activin A were discovered as proteins regulating the
release of follicle-stimulating hormone (Ling et al, 1986; Vale et al,
1986). Since then activin A has become the best characterised
member of the inhibin/activin family. Besides its function in the
pituitary, it is involved in many physiological processes, including
embryonic development, erythroid differentiation, fibrosis,
inflammation, cell proliferation and apoptosis as reviewed recently
(Rodgarkia-Dara et al, 2006). Induction of apoptosis by activin A
was described for the first time in rat liver and primary
hepatocytes (Schwall et al, 1993). In the following years, several
studies revealed a potent growth inhibitory role of activin A in the
liver (Yasuda et al, 1993; Hully et al, 1994; Kogure et al, 1995), and
activin A and TGFb turned out as the two dominant hepatic
growth inhibitors that counterbalance or terminate growth
induction by a large number of stimulating factors.
In this study, somewhat surprisingly the expression of INHBA
and also the protein level were not downregulated in the majority
of tumour-adjacent and HCC samples studied, but even increased
in several HCC. How HCC cells may escape from the proapoptotic
and antiproliferative action of activin A? Activin A activity is
known to be antagonised by several extracellular factors, including
follistatin (Esch et al, 1987; Mashima et al, 1995), fstl3 (Tsuchida
et al, 2000) and cripto (Gray et al, 2003). We described previously
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Figure 2 Immunohistochemical localisation of inhibin/activin proteins in HCC and tumour-adjacent liver. (A) Microphotographs show cytoplasmatic
staining of inhibin a in carcinoma cells (i) and (iii), whereas hepatocytes (ii) and (iv) and non-parenchymal cells are negative. (B) Activin/inhibin staining for
subunits bA, bB and bE is high in tumour and adjacent parenchymal tissue. Inlets: non-immune serum; scale bars: 100mm.
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san upregulation of follistatin expression in rat and human liver
tumours (Grusch et al, 2006).
Similarly, inhibin A, the heterodimer of INHA and INHBA gene
products, antagonises the anti-proliferative action of activin A by
competitive binding to cell surface activin type II receptors
(ActRIIA/B) and inhibits downstream signalling in liver cells
(Xu et al, 1995; Lewis et al, 2000; Massague, 2000). In the
inhibin a nulled mouse, activin A serum levels were enhanced
more than 10-fold, leading to apoptosis and necrosis in the liver
(Matzuk et al, 1994). Our results revealed increases of INHA mRNA
in most of the tumour-adjacent and HCC samples studied
amounting to 9- and 225-fold increases, respectively, over disease-
free liver (Figure 1, Table 2). Inhibin a protein also was clearly
detectable, at least in some HCC (Figure 2, Supplementary Figure 3).
The pronounced upregulation of INHA may lead to a shift from
production of the activin A homodimer to the inhibin A hetero-
dimer. These data suggest that high INHA expression blocks the
activin A signal in HCC and also in tumour-adjacent tissue (which
may contain cirrhosis, a cancer prestage), and thereby provides for,
or contributes to, the growth advantage of tumour cells.
Similarly, the 12-fold mean increase in INHBB expression in
HCC compared with normal liver may cause a shift from activin A
to activin AB protein, which reportedly was less inhibitory than
activin A on rat hepatocyte proliferation (Niimi et al, 2002). In
conclusion, the enhanced expression of INHA or INHBB detected
in 80% of our HCC patients may serve as alternative or additional
regulators besides follistatin, fstl3 and cripto, overriding the
antiproliferative and proapoptotic action of activin A.
Expression of INHBB in normal human liver was as high as in
testis (Figure 4), one of the organs with known high expression
(Roberts, 1997; Vejda et al, 2002). Up to now only few data on bB
expression levels in human liver are available. In human fetal liver
INHBB was detected by northern assay at similar levels as INHBA,
but less expressed than in fetal testis (Tuuri et al, 1994). Sjoholm
et al (2006) detected very low levels of INHBB by RT–PCR after
normalising to cyclophilin A, whereas in a large-scale expression
study on the same samples (Su et al, 2002) liver INHBB levels were
higher than in pituitary, but lower than in testis (http://
biogps.gnf.org/; INHBB; 3625_at Entrez Gene). So far, because of
its low or negligible occurrence in rodent liver the role of INHBB in
this organ has not been elucidated.
Interestingly, some extrahepatic tumours also show upregula-
tion of INHA and/or INHBB. INHBB was upregulated in malignant
endometrial tissues (Worbs et al, 2007) and in malignant but not
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Figure 3 Expression of inhibin subunits in human tissues. Ct values detected in the various tissues ranged from 24.0 to 36.0 for INHA, for INHBA from 27.5
to 37.0, for INHBB from 24.5 to 35.5, for INHBC from 26.0 to 38.5 and for INHBE from 24.5 to 36.5. Expression below detection limits is marked by
asterisks. The respective lowest expressing tissue (arrow) was used as calibrator and set 1, the expression levels of the others were depicted as fold increase
in logarithmic scale. Disease-free liver is shown in grey, HCC expression levels by gridded bars. PBMC, peripheral blood mononuclear cells.
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sin benign pheochromocytomas (Salmenkivi et al, 2001). Over-
expression of the INHA subunit is pronounced in gonadal stromal
tumours and even used as tumour marker (Fuller et al, 1999;
Fine and Li, 2003; Ciris et al, 2004). Similarly, elevated serum levels
of the inhibin a peptide were found in granulosa cell tumour
patients (Burger et al, 2001). No inhibin a protein was detected in
liver (Renshaw and Granter, 1998; Lau et al, 2002), but was
reportedly found in 17 out of 19 HCC by immunohistochemistry
(McCluggage et al, 1997; Vrettou et al, 2005). However, this finding
was not confirmed on 23 HCC and suggested to be a staining
artefact caused by endogenous biotin (Iezzoni et al, 1999). Another
study classified a INHA positive hepatic adenocarcinoma as
cholangiocarcinoma (Vrettou et al, 2005). Our investigation
provides strong evidence for expression of INHA in HCC as
cross-reactivity with biotin is excluded by using a biotin-free
detection system and the specificity of staining was shown by
incubation without antibodies or non-immune serum.
In summary, we have shown a pronounced upregulation of
INHA and a more moderate increase in INHBB in most of the HCC
samples analysed. Furthermore, marked differences in expression
of inhibin genes between rodent and human liver were found.
These new insights provide important hints to the largely
unknown functions of the inhibins and activins in the liver and
during hepatocarcinogenesis. Understanding how cancer cells
escape from the action of activin A, a major growth inhibitor in
the liver, may elucidate key dysfunctions of signalling in HCC and
eventually open up new avenues to molecular therapy of this
disease.
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